Commitments and Contingencies	6 Months Ended
Jun. 30, 2019
Commitments and Contingencies
Commitments and Contingencies	I.Commitments and Contingencies Collaborations The Company is contractually obligated to make potential future success-based development, regulatory, or sales milestone payments in conjunction with certain collaborative agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. As of June 30, 2019, the maximum amount that may be payable in the future under the Company’s current collaborative agreements is $80.0 million. Manufacturing Commitments As of June 30, 2019, the Company has noncancelable obligations under agreements related to in-process and future manufacturing of cytotoxic agents required for clinical supply of the Company’s product candidates totaling $1.5 million, all of which will be paid in 2019. Additionally, in 2018, the Company executed a commercial agreement with one of its manufacturers for future production of antibody through calendar 2025. In May 2019, the agreement was amended to reduce the number of committed antibody batches for an agreed-upon exit fee, which was recorded as research and development expense in the first quarter of 2019. As of June 30, 2019, the Company’s noncancelable commitment ranges from €2.3 to €15.1 million pursuant to contingent terms of the agreement, including the manufacturer’s ability to fill the Company’s unused capacity with production for other customers.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

I.Commitments and Contingencies

Collaborations

The Company is contractually obligated to make potential future success-based development, regulatory, or sales milestone payments in conjunction with certain collaborative agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be

required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. As of June 30, 2019, the maximum amount that may be payable in the future under the Company’s current collaborative agreements is $80.0 million.

Manufacturing Commitments

As of June 30, 2019, the Company has noncancelable obligations under agreements related to in-process and future manufacturing of cytotoxic agents required for clinical supply of the Company’s product candidates totaling $1.5 million, all of which will be paid in 2019.

Additionally, in 2018, the Company executed a commercial agreement with one of its manufacturers for future production of antibody through calendar 2025. In May 2019, the agreement was amended to reduce the number of committed antibody batches for an agreed-upon exit fee, which was recorded as research and development expense in the first quarter of 2019. As of June 30, 2019, the Company’s noncancelable commitment ranges from €2.3 to €15.1 million pursuant to contingent terms of the agreement, including the manufacturer’s ability to fill the Company’s unused capacity with production for other customers.